1stOncology™: Cancer Intelligence Service – Page 5739 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

On March 13, 2023 Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), reported that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023 (Press release, Liminal BioSciences, MAR 13, 2023, View Source,-2023 [SID1234628599]). Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back. You can also dial direct to be entered to the call by an Operator by dialing 416-764-8609 and 888-390-0605, using the following passcode: 77593817. An audio replay of the call will be available as of Thursday March 16, 2023 at 11:30 am (ET). The numbers to access the audio replay are 416-764-8677 and 1-888-390-0541 using the following password (593817 #). A live audio webcast of the conference call will be available by clicking here.

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

On March 13, 2023 ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), reported an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA (Press release, ProMIS Neurosciences, MAR 13, 2023, View Source [SID1234628598]). The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).

Oral Presentation:

Title: Rational Design of a Vaccine for Alzheimer’s Disease Using Computationally-Derived Conformational B Cell Epitopes to Selectively Target Toxic Amyloid-Beta Oligomers
Session: S26: Experimental Therapeutics in Dementia (abstract #4532)
Presenter: Dr. Johanne Kaplan
Date & Time: April 25, 2023 at 1:36 p.m. ET

Poster Presentations:

Title: Protection Against Toxic Amyloid-Beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s Disease
Session: P1: Aging and Dementia: Basic Science (abstract #4597)
Presenter: Dr. Johanne Kaplan
Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET

Title: RACK1 Knockdown Is a Potential Therapeutic Target in ALS and FTLD-TDP
Session: P1: Aging and Dementia: Basic Science (abstract #3494)
Presenter: Dr. Neil Cashman
Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

On March 13, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33rd Annual Healthcare Conference, which will take place March 13th – 15th, 2023 (Press release, DiaMedica, MAR 13, 2023, View Source [SID1234628597]).

Mr. Pauls is scheduled to present at 2:40 p.m. Eastern Time on Wednesday, March 15, 2023. In addition to the presentation, Mr. Pauls will be available for one-on-one investor meetings throughout the conference. Investors that are interested in arranging a meeting should contact their Oppenheimer representative.

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET

Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2022 and provide guidance on upcoming milestones. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.

To register for the webcast, sign up at the link below: View Source

A replay of the webcast will be available after the call on the investor relations section of the Company’s website at ir.lanternpharma.com.

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

On March 13, 2023 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank (Press release, Lantern Pharma, MAR 13, 2023, View Source [SID1234628595]). Lantern’s cash, cash equivalents, and marketable securities are managed across top-tier financial institutions and with a multiple-tiered account approach. Lantern’s cash, cash equivalents, and marketable securities are sufficient to continue development and current operations into 2025.